MX2024001367A - Nuevas sales farmaceuticas y formas polimorficas de un inhibidor de erbb y btk. - Google Patents
Nuevas sales farmaceuticas y formas polimorficas de un inhibidor de erbb y btk.Info
- Publication number
- MX2024001367A MX2024001367A MX2024001367A MX2024001367A MX2024001367A MX 2024001367 A MX2024001367 A MX 2024001367A MX 2024001367 A MX2024001367 A MX 2024001367A MX 2024001367 A MX2024001367 A MX 2024001367A MX 2024001367 A MX2024001367 A MX 2024001367A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical salts
- polymorphic forms
- erbb
- btk inhibitor
- btk
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
- C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021110048 | 2021-08-02 | ||
| PCT/CN2022/109065 WO2023011358A1 (en) | 2021-08-02 | 2022-07-29 | Novel pharmaceutical salts and polymorphic forms of an erbb and btk inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001367A true MX2024001367A (es) | 2024-02-27 |
Family
ID=85154265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001367A MX2024001367A (es) | 2021-08-02 | 2022-07-29 | Nuevas sales farmaceuticas y formas polimorficas de un inhibidor de erbb y btk. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250197377A1 (OSRAM) |
| EP (1) | EP4380924A4 (OSRAM) |
| JP (1) | JP2024529533A (OSRAM) |
| KR (1) | KR20240042640A (OSRAM) |
| CN (1) | CN117794902A (OSRAM) |
| AR (1) | AR126673A1 (OSRAM) |
| AU (1) | AU2022324410A1 (OSRAM) |
| CA (1) | CA3224748A1 (OSRAM) |
| MX (1) | MX2024001367A (OSRAM) |
| TW (1) | TW202321223A (OSRAM) |
| WO (1) | WO2023011358A1 (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024261740A1 (en) | 2023-06-23 | 2024-12-26 | Assia Chemical Industries, Ltd. | Solid state forms of sunvozertinib |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2866857C (en) * | 2012-03-15 | 2021-03-09 | Celgene Avilomics Research, Inc. | Salts of an epidermal growth factor receptor kinase inhibitor |
| CN105384694B (zh) * | 2014-08-22 | 2020-09-04 | 四川海思科制药有限公司 | 一种取代的氨基嘧啶衍生物及其制备方法和药物用途 |
| CN106905245B (zh) * | 2015-12-23 | 2021-06-25 | 正大天晴药业集团股份有限公司 | 2,4-二取代的嘧啶类化合物 |
| CN106083736A (zh) * | 2016-06-21 | 2016-11-09 | 郑州泰基鸿诺医药股份有限公司 | 一种嘧啶类化合物、egfr抑制剂及其应用 |
| TWI798334B (zh) * | 2018-01-31 | 2023-04-11 | 大陸商迪哲（江蘇）醫藥股份有限公司 | Ｅｒｂｂ／ｂｔｋ抑制劑 |
| WO2019177375A1 (ko) * | 2018-03-13 | 2019-09-19 | 포로노이바이오 주식회사 | 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
-
2022
- 2022-07-29 CA CA3224748A patent/CA3224748A1/en active Pending
- 2022-07-29 TW TW111128540A patent/TW202321223A/zh unknown
- 2022-07-29 EP EP22852071.4A patent/EP4380924A4/en active Pending
- 2022-07-29 MX MX2024001367A patent/MX2024001367A/es unknown
- 2022-07-29 AU AU2022324410A patent/AU2022324410A1/en active Pending
- 2022-07-29 KR KR1020247007187A patent/KR20240042640A/ko active Pending
- 2022-07-29 WO PCT/CN2022/109065 patent/WO2023011358A1/en not_active Ceased
- 2022-07-29 JP JP2024506641A patent/JP2024529533A/ja active Pending
- 2022-07-29 US US18/293,778 patent/US20250197377A1/en active Pending
- 2022-07-29 CN CN202280053629.5A patent/CN117794902A/zh active Pending
- 2022-08-02 AR ARP220102058A patent/AR126673A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4380924A4 (en) | 2025-10-01 |
| AR126673A1 (es) | 2023-11-01 |
| CA3224748A1 (en) | 2023-02-09 |
| TW202321223A (zh) | 2023-06-01 |
| EP4380924A1 (en) | 2024-06-12 |
| WO2023011358A1 (en) | 2023-02-09 |
| AU2022324410A1 (en) | 2024-01-18 |
| CN117794902A (zh) | 2024-03-29 |
| JP2024529533A (ja) | 2024-08-06 |
| KR20240042640A (ko) | 2024-04-02 |
| US20250197377A1 (en) | 2025-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123661T1 (el) | Κρυσταλλικη μορφη ενος αναστολεα της mdm2 | |
| CO2022016323A2 (es) | Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica que constituye el mismo | |
| CO2022015638A2 (es) | Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso | |
| CY1124359T1 (el) | Ενωσεις και συνθεσεις για ρυθμιση δραστικοτητων κινασης μεταλλακτικου egfr | |
| ECSP22091485A (es) | Imidazolpiridazinas como moduladores de il-17 | |
| PE20191755A1 (es) | Derivados de pirazol como inhibidores de malt 1 | |
| MX2023011933A (es) | Moduladores del linfoma de linaje b de casitas de ligasa e3 b (cbl-b) y usos de estos. | |
| CL2024002623A1 (es) | Formas solidas, sales y procesos de preparacion de un inhibidor de cdk2. | |
| CR20190124A (es) | Inhibidores de ssao de aminopirimidina | |
| CL2011001356A1 (es) | Formas cristalinas a1, h1, nf3 y nf6 de clorhidrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il)-bencil}-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo; proceso de preparacion; composicion y combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento o profilaxis de cancer, tumores, sarcoma, entre otros. | |
| CL2021001537A1 (es) | Formas cristalinas y formas de sal de un inhibidor de cinasa | |
| MX2020007947A (es) | Inhibidores de erbb/btk. | |
| PE20170268A1 (es) | Compuestos de heteroarilo para la inhibicion de cinasa | |
| MX2022001562A (es) | Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1). | |
| PE20181015A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| MX2024009943A (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
| CL2021003455A1 (es) | Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida | |
| MX2022013650A (es) | Imidazopirimidinas como moduladores de il-17. | |
| CO2021005141A2 (es) | Formas cristalinas sólidas de n-(1-((2-(dimetilamino)etil)amino)-2-metil-1-oxopropano-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5-trihidroxi-6-(metiltio)tetrahidro-2h-pirano-2-il)bencil)fenil)butanamida y métodos para su síntesis | |
| CO2024009144A2 (es) | Inhibidores de cinasa met | |
| DOP2024000085A (es) | Compuestos dirigidos a pmp22 para el tratamiento de la enfermedad de charcot-marie-tooth | |
| PY1886949A (es) | Inhibidor del receptor del factor de crecimiento epidérmico | |
| MX2019012967A (es) | Cristal de base libre de derivados benzofurano y metodo de preparacion. | |
| MX2021014842A (es) | Sales cristalinas no higroscopicas de un compuesto de pirazol y composiciones farmaceuticas y uso de las mismas. | |
| CO2024012427A2 (es) | Pirimidinas para degradar la tirosina quinasa de bruton |